Content Validity of HIT-6 as a Measure of Headache Impact in People With Migraine: A Narrative Review
- PMID: 31811654
- PMCID: PMC7003926
- DOI: 10.1111/head.13701
Content Validity of HIT-6 as a Measure of Headache Impact in People With Migraine: A Narrative Review
Abstract
Background: The short-form Headache Impact Test (HIT-6) is a widely used patient-reported outcome measure that assesses the negative effects of headaches on normal activity. It was developed using the general headache population and prior to the establishment of the now well-accepted FDA patient-reported guidance.
Objective: The objective of this narrative review was to examine existing qualitative research in patients with migraine and headache, providing insight into the relevance and meaningfulness of HIT-6 items to the lives of migraine patients.
Methods: Articles were identified through database searches (National Library of Medicine and Google Scholar) and review of reference lists of candidate articles.
Results: A total of 3227 articles were identified through database and hand searching. Of these, 12 contained patient- or expert-generated qualitative information regarding headache patients' experience (8 specific to migraine [episodic and chronic] patients and 4 citing general headache patients). The combined publications described a total of 283 patient interviews. Overarching themes and specific information were identified that provide support of the relevance of content for each HIT-6 item to migraine patients' lives. Identified effects of headaches on patients with migraine included limitations in daily activities, needing to lie down during headaches, feeling tired, being irritated by headaches, difficulty concentrating, and the experience of pain. Further, previous research specific to the HIT-6 indicated that patients understood the instructions, items, and response scales as intended by the instrument authors.
Conclusions: This narrative literature review demonstrates qualitative research support for the relevance of the items of the HIT-6 in migraine patients, supporting its ongoing use in clinical migraine research and practice.
Keywords: chronic migraine; epidemiology; outcomes research; short-form Headache Impact Test.
© 2019 The Authors. Headache: The Journal of Head and Face Pain published by Wiley Periodicals, Inc. on behalf of American Headache Society.
Figures
Similar articles
-
Development and validation of a novel patient-reported outcome measure in people with episodic migraine and chronic migraine: The Activity Impairment in Migraine Diary.Headache. 2022 Jan;62(1):89-105. doi: 10.1111/head.14229. Epub 2021 Dec 28. Headache. 2022. PMID: 34962305 Free PMC article.
-
Determining Thresholds for Meaningful Change for the Headache Impact Test (HIT-6) Total and Item-Specific Scores in Chronic Migraine.Headache. 2020 Oct;60(9):2003-2013. doi: 10.1111/head.13946. Epub 2020 Aug 30. Headache. 2020. PMID: 32862469 Free PMC article. Clinical Trial.
-
A narrative review on the burden of migraine: when the burden is the impact on people's life.J Headache Pain. 2019 Apr 25;20(1):41. doi: 10.1186/s10194-019-0993-0. J Headache Pain. 2019. PMID: 31023226 Free PMC article. Review.
-
Meta-Synthesis on Migraine Management.Headache. 2018 Jan;58(1):22-44. doi: 10.1111/head.13212. Epub 2017 Nov 21. Headache. 2018. PMID: 29159874 Review.
-
Development and exploration of the content validity of a patient-reported outcome measure to evaluate the impact of migraine- the migraine physical function impact diary (MPFID).Health Qual Life Outcomes. 2017 Nov 17;15(1):224. doi: 10.1186/s12955-017-0799-1. Health Qual Life Outcomes. 2017. PMID: 29149901 Free PMC article.
Cited by
-
Relationship between Contingent Negative Variation and afterimage duration in migraine patients.Front Neurol. 2024 May 17;15:1401212. doi: 10.3389/fneur.2024.1401212. eCollection 2024. Front Neurol. 2024. PMID: 38827574 Free PMC article.
-
Reducing the Impact of Headache and Allodynia Score in Chronic Migraine: An Exploratory Analysis from the Real-World Effectiveness of Anti-CGRP Monoclonal Antibodies Compared to Onabotulinum Toxin A (RAMO) Study.Toxins (Basel). 2024 Apr 7;16(4):178. doi: 10.3390/toxins16040178. Toxins (Basel). 2024. PMID: 38668603 Free PMC article.
-
Structural equation modeling for identifying the drivers of health-related quality of life improvement experienced by patients with migraine receiving eptinezumab.J Headache Pain. 2024 Mar 28;25(1):45. doi: 10.1186/s10194-024-01752-z. J Headache Pain. 2024. PMID: 38549121 Free PMC article.
-
Association between patent foramen ovale and migraine: evidence from a resting-state fMRI study.Brain Imaging Behav. 2024 Feb 21. doi: 10.1007/s11682-024-00868-9. Online ahead of print. Brain Imaging Behav. 2024. PMID: 38381323
-
Real-world experience with calcitonin gene-related peptide-targeted antibodies for migraine prevention: a retrospective observational cohort study at two Japanese headache centers.BMC Neurol. 2024 Jan 18;24(1):32. doi: 10.1186/s12883-023-03521-y. BMC Neurol. 2024. PMID: 38238659 Free PMC article.
References
-
- GBD 2016 Disease and Injury Incidence and Prevalence Collaborators . Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990‐2016: A systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017;390:1211‐1259. - PMC - PubMed
-
- Bigal ME, Serrano D, Reed M, Lipton RB. Chronic migraine in the population: Burden, diagnosis, and satisfaction with treatment. Neurology. 2008;71:559‐566. - PubMed
-
- Minen MT, Begasse De Dhaem O, Kroon Van Diest A, et al. Migraine and its psychiatric comorbidities. J Neurol Neurosurg Psychiatry. 2016;87:741‐749. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical